US CDC asks state to be ready to distribute COVID-19 vaccines by 1 November

Providence: The federal government has told states to prepare for a coronavirus vaccine to be ready to distribute by 1 November. The timeline raised concern among public health experts about an “October surprise” – a vaccine approval driven by political considerations ahead of a presidential election, rather than science. In a letter to governors dated 27 August, Robert Redfield, director of the US Centers for Disease Control and Prevention, said states in the near future will receive permit applications from McKesson Corporation, which has contracted with CDC to distribute vaccines to places including state and local health departments and hospitals. CDC urgently requests your assistance in expediting applications for these distribution facilities and, if necessary, asks that you consider waiving requirements that would prevent these facilities from becoming fully operational by 1 November, 2020, Redfield wrote. He wrote that any waivers will not compromise the safety or effectiveness of the vaccine. The Associated Press obtained the letter, which was first reported by McClatchy. The CDC also sent three planning documents to some health departments that included possible timelines for when vaccines would be available. The documents are to be used to develop plans for early vaccination when the supply might be constrained, according to one of the documents, which outlined a scenario in which a vaccine could be available as soon as the end of October. The COVID-19 vaccine landscape is evolving and uncertain, and these scenarios may evolve as more information is available, the document reads. Another of the documents says that limited COVID-19 vaccine doses may be available by early November and that supply will increase substantially in 2021. It also states that initially available vaccines will either be approved by the Food and Drug Administration or authorized by the agency under its emergency powers. The documents encourage health officials to work out now which groups to prioritize for a vaccine, identify providers who will administer vaccine, and take other steps to prepare. The planning documents were first reported by The New York Times. Redfield told Yahoo Finance that officials were preparing for what I anticipate will be a reality, is that there’ll be one or more vaccines available for us in November, December. James S Blumenstock, a senior vice president at the Association of State and Territorial Health Officials, said the CDC was offering an aggressive but necessary timetable" and that public health agencies were mobilising to prepare detailed plans. Several public health experts pointed out that final stage trials of experimental vaccines are still recruiting, and are at best halfway through that process. The vaccines are two doses, and each is given a month apart. The experts told they did not understand how there could be adequate data on whether the vaccines work and are safe before 1 November. Being ready is reasonable. Cutting short phase 3 trials before you get the information you need isn’t, said Dr. Paul Offit, a Children’s Hospital of Philadelphia immunisation expert who sits on the FDA’s vaccine advisory committee. Peter Hotez, dean of Baylor University’s tropical medicine school, said he was very concerned about whether the FDA would use an emergency use authorisation to approve a vaccine before knowing whether it works and is safe. “It gives the appearance of a stunt rather than an expression of public health concern,? Hotez said. [caption id=“attachment_8531451” align=“alignnone” width=“640”]  A new visualisation of the COVID-19 virus. Image courtesy Fusion Medical Animation[/caption] FDA Commissioner Stephen Hahn previously said the agency wouldn’t cut corners in evaluating vaccines, though it would aim to expedite its work. He told the Financial Times this week that it might be appropriate to approve a vaccine before clinical trials were complete if the benefits outweighed the risks. Unlike a therapeutic that is given to sick people who may have no alternative, a vaccine is given to healthy people, so you have a much higher burden of proof, said Ashish Jha, dean of Brown University’s public health school. I think it’s reasonable to be communicating to hospitals and saying at some point late in the fall or winter,” Jha said. November feels awfully early. Michael Osterholm, a University of Minnesota infectious disease expert, said he was concerned about an October surprise with a vaccine being rushed through ahead of the election. The public health community wants a safe and effective vaccine as much as anybody could want it, Osterholm said. But the data have to be clear and compelling. He said there was a credibility gap between doctors and the FDA about how rigorously products are being evaluated during the pandemic. Some state officials said Wednesday that they were working on the next steps while still awaiting details from CDC, and some sounded a cautious note. Kris Ehresmann, Minnesota’s infectious disease director, told the AP the state would only move forward once we know it is safe. She said they would take their lead from the CDC’s Advisory Committee on Immunization Practices, which she said will only recommend a vaccine that has met the safety criteria. The Oregon Board of Pharmacy said it would expedite McKesson’s applications but wouldn’t waive requirements necessary to maintain public health and safety.